By Peter Su (Contributor, Forbes)
See Peter Su’s here: Bio
Published June 9, 2026, 5:09 pm EDT
Link to original article: Click here to view.
Historically, cannabis companies operating in the United States have been locked out of one of the most fundamental tools available to American businesses: the ability to list on a major U.S. stock exchange. On June 5, 2026, that changed.
Trulieve Cannabis Corp. announced that its shares have been approved for listing on the New York Stock Exchange, with trading set to begin under the ticker “TRLV” on June 10. The Tallahassee-based company bills itself as a leading medical cannabis operator in the U.S. But the headline isn’t the company—it’s the moment. This is a first, and in an industry that has been waiting years for mainstream legitimacy, firsts matter.
How Trulieve Got Here
The path to the NYSE wasn’t simply a matter of filing paperwork. It required an act of federal policy, a significant corporate restructuring and a level of legal and financial engineering that most companies never have to attempt.
Acting attorney general Todd Blanche reclassified medical marijuana to Schedule III in April 2026, following an executive order by President Trump in December 2025. That final order rescheduled state-licensed medical marijuana products and created a pathway for DEA registration for state-licensed medical marijuana businesses. Without that move, none of this would have been possible—cannabis as a Schedule I substance made a major exchange listing essentially a legal impossibility.
But rescheduling alone wasn’t enough. Because current exchange policy does not permit listed companies to consolidate businesses involved in non-medical marijuana, Trulieve had to deconsolidate its operations in markets serving both medical and adult-use customers. In practice, that meant spinning off its mixed-use assets—branded under its Harvest subsidiary—into a separate entity. The transaction included a new LLC structure, a $14.8 million sale of a 10% voting stake in Harvest to an outside party, a protection agreement and a management services agreement. What remains on Trulieve’s consolidated books is a purely medical cannabis business: 206 dispensaries backed by 3.5 million square feet of DEA-registered production capacity.
What The Experts Are Saying
Those who have spent years watching this industry from the inside see the move as genuinely historic—but they’re careful not to oversell it.
Kraig Fox, founder and CEO of Reklaim Credit Solutions, a commercial credit rating agency for the regulated cannabis industry, calls it via email “a highly sophisticated piece of financial and legal structuring and likely the first of many to follow.” Fox sees the listing as delivering “true liquidity and access to a deeper, more institutional shareholder base”—a real inflection point for an industry long shut out of mainstream capital markets.
Neil Kaufman, managing member of cannabis law firm Kaufman McGowan PLLC, is more measured about what this actually unlocks. While he acknowledges the significance of the listing, he argues the more meaningful threshold comes later: “The key to unlocking the U.S. capital markets will be when the U.S. national securities exchanges permit straight-up listings by recreational plant-touching companies.” That, he says via email, will require more than rescheduling—it would need either broader federal legality or a version of the SAFE Banking Act that explicitly covers exchanges and securities custodians, “all of which to date have refused to hold custody of U.S. recreational cannabis companies.” Which echoes similar thoughts on the banking or financing side of the industry.
Fox’s optimism and Kaufman’s caution aren’t necessarily in conflict. Both reflect the same underlying reality: Trulieve has cleared a significant hurdle, but the structure required to do so—surgically separating its medical and adult-use operations—is one its peers weren’t willing or able to replicate. Curaleaf, one of the other major multistate operators, has acknowledged that uplisting will only be possible once additional regulatory guidance is in place.
Marc Hauser, general counsel of Khalifa Kush and a cannabis law professor at UNLV and Northwestern, adds another dimension: “It’s definitely a win for Trulieve, which lost its bet on Florida adult-use, so kudos to them—and their lawyers and accountants—for pulling this off.” That context matters.
The NYSE listing isn’t just a strategic triumph; it’s also a pivot. Having spent more than $145 million backing Florida’s failed 2024 adult-use ballot measure—Amendment 3, which fell short of the required 60% supermajority with 56% of the vote—Trulieve needed a new story to tell investors, and this is it. The harder question, as Hauser puts it via email, is “convincing institutional investors that this industry is investible.”
This last point is poignant, the presumption that uplisting will bring liquidity is based on one very important factor–investors. Will investors, in particular institutional investors, invest into cannabis? Certainly, one would assume flipping from a net loss to a net profit with presumed 280E relief would go a long way toward that goal.
The Risks Are Real
The optimism here is warranted, but so is the caution.
Fox points to two key vulnerabilities: the possibility of legal challenges to the Schedule III rescheduling itself and the fact that Trulieve is now operating in regulatory territory without a clear precedent. Unlike other Schedule III controlled substances—think acetaminophen with codeine or testosterone—Trulieve operates a network of 206 retail dispensaries with millions of customers, a commercial scale that has no real analog in the existing Schedule III framework. In a sense, some of this is being made up as we go, and doing so at scale with public investors watching.
The Schedule III reclassification also carries financial stakes well beyond the listing itself. As a Schedule I substance, cannabis subjected state-licensed operators to Section 280E of the federal tax code, which bars businesses trafficking in controlled substances from deducting ordinary operating expenses—effectively taxing revenue rather than profit, with effective federal tax rates documented as high as 80% in some cases. Relief from that provision alone could dramatically improve the financial profile of medical cannabis operators.
What Investors Will Be Watching
Getting approved for the NYSE is one thing. Attracting the institutional capital that comes with a major listing is another challenge entirely—and the factors that will draw investors in or keep them on the sidelines are worth spelling out.
On the positive side, institutional investors will be watching for liquidity and price stability in early trading, the durability of the Schedule III reclassification against potential legal challenges and whether Trulieve’s newly streamlined medical-only business can post clean, improving financial results now that 280E no longer distorts its books. A track record of regulatory compliance under the new DEA registration framework would also go a long way toward reassuring fund managers who have historically been wary of cannabis.
The hesitation factors are equally concrete. The separation structure—with Harvest operating as a distinct entity—adds complexity that can create friction in how markets value the company over time. Any rollback of the rescheduling order, whether through litigation or a future administration, would materially change the picture. And more broadly, cannabis still carries reputational risk for institutional investors: Many funds have mandates or stakeholder pressures that keep them away from the sector regardless of legal status.
What is undeniable is that Trulieve has done something no U.S. plant-touching cannabis operator has ever done before. When trading opens on June 10 under the ticker TRLV, every other major cannabis operator—and every investor who has been sitting on the sidelines—will be watching closely.
If the institutional money follows, it won’t just be a win for Trulieve. It will be the moment the American cannabis industry finally grew up.
ATTORNEY ADVERTISING